Manufacturing, Cell Therapies

Lykan Bioscience and Vineti Partner to Advance Cell Therapies from Clinic to Commercialization

August 13, 2021

Lykan Bioscience and Vineti will combine their capabilities to streamline process development and manufacturing to move cell therapies through clinical phases to commercialization.

Lonza and Sheba Medical Center Demonstrate Successful Cell Therapy Results with Cocoon Automated Platform

August 12, 2021

Lonza and Sheba Medical Center have successfully dosed four patients with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon automated manufacturing platform.

AGC Biologics Acquires Cell and Gene Therapy Commercial Manufacturing Facility

August 09, 2021

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

Catalent Finalizes RheinCell Therapeutics Acquisition

August 06, 2021

Catalent finalizes their acquisition of iPSC developer and manufacturer RheinCell Therapeutics.

Designing Incubators for Cell Therapy Manufacturing

August 03, 2021

Controlling conditions and preventing contamination are crucial for cell growth.

PerkinElmer to Acquire BioLegend in $5.25-Billion Deal

July 27, 2021

PerkinElmer has entered into an agreement to acquire BioLegend, a global developer and manufacturer, in a deal valued at $5.25 billion.

BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Manufacturing Facility

July 21, 2021

BioNTech will acquire a TCR cell therapy R&D platform as well as a manufacturing facility in Gaithersburg, Md., from Kite, a Gilead company.

Nkarta Establishes New NK Cell Therapy Manufacturing Facility and Headquarters

July 21, 2021

Nkarta will establish a new combined scalable NK cell therapy manufacturing facility and corporate headquarters in South San Francisco, Calif.

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing

July 21, 2021

Cellares has entered into a strategic relationship with Poseida Therapeutics to advance a closed, automated, and scalable cell therapy manufacturing system.

Lonza to Supply Prequalified Hepatocytes for Use on CN Bio’s Organ-on-a-Chip Range

July 20, 2021

The companies work to develop and supply advanced cell models that better reflect an in-vivo environment to improve drug discovery accuracy and efficiency.